198 related articles for article (PubMed ID: 29774635)
41. Aripiprazole in the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorder in Japan: A Randomized, Double-blind, Placebo-controlled Study.
Ichikawa H; Mikami K; Okada T; Yamashita Y; Ishizaki Y; Tomoda A; Ono H; Usuki C; Tadori Y
Child Psychiatry Hum Dev; 2017 Oct; 48(5):796-806. PubMed ID: 28004215
[TBL] [Abstract][Full Text] [Related]
42. Safety and effectiveness of lurasidone for the treatment of schizophrenia in Asian patients: Results of a 26-week open-label extension study.
Higuchi T; Ishigooka J; Iyo M; Hagi K
Asia Pac Psychiatry; 2020 Mar; 12(1):e12377. PubMed ID: 31837113
[TBL] [Abstract][Full Text] [Related]
43. Efficacy and Safety of Blonanserin Oral Tablet in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study.
Saito T; Sugimoto S; Sakaguchi R; Nakamura H; Ishigooka J
J Child Adolesc Psychopharmacol; 2022 Feb; 32(1):12-23. PubMed ID: 35133884
[No Abstract] [Full Text] [Related]
44. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia.
Hirayasu Y; Sato S; Takahashi H; Iida S; Shuto N; Yoshida S; Funatogawa T; Yamada T; Higuchi T
BMC Psychiatry; 2016 Mar; 16():66. PubMed ID: 26980460
[TBL] [Abstract][Full Text] [Related]
45. Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Takekita Y; Fabbri C; Kato M; Nonen S; Sakai S; Sunada N; Koshikawa Y; Wakeno M; Okugawa G; Kinoshita T; Serretti A
Eur Arch Psychiatry Clin Neurosci; 2015 Oct; 265(7):579-88. PubMed ID: 26016467
[TBL] [Abstract][Full Text] [Related]
46. Intramuscular olanzapine versus intramuscular aripiprazole for the treatment of agitation in patients with schizophrenia: A pragmatic double-blind randomized trial.
Kittipeerachon M; Chaichan W
Schizophr Res; 2016 Oct; 176(2-3):231-238. PubMed ID: 27461399
[TBL] [Abstract][Full Text] [Related]
47. Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial.
Kryzhanovskaya L; Schulz SC; McDougle C; Frazier J; Dittmann R; Robertson-Plouch C; Bauer T; Xu W; Wang W; Carlson J; Tohen M
J Am Acad Child Adolesc Psychiatry; 2009 Jan; 48(1):60-70. PubMed ID: 19057413
[TBL] [Abstract][Full Text] [Related]
48. The safety and tolerability of aripiprazole once-monthly as maintenance treatment for bipolar I disorder: A double-blind, placebo-controlled, randomized withdrawal study.
Calabrese JR; Sanchez R; Jin N; Amatniek J; Cox K; Johnson B; Perry PP; Hertel P; Such P; McQuade RD; Nyilas M; Carson WH
J Affect Disord; 2018 Dec; 241():425-432. PubMed ID: 30145513
[TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations.
Daniel DG; Currier GW; Zimbroff DL; Allen MH; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):170-7. PubMed ID: 17522560
[TBL] [Abstract][Full Text] [Related]
50. Comparison of ziprasidone and aripiprazole in acutely ill patients with schizophrenia or schizoaffective disorder: a randomized, double-blind, 4-week study.
Zimbroff D; Warrington L; Loebel A; Yang R; Siu C
Int Clin Psychopharmacol; 2007 Nov; 22(6):363-70. PubMed ID: 17917555
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
[TBL] [Abstract][Full Text] [Related]
52. A Comparative Study of Short Term Efficacy of Aripiprazole and Risperidone in Schizophrenia.
Kumar P B S; Pandey RS; Thirthalli J; Kumar P T S; Kumar C N
Curr Neuropharmacol; 2017 Nov; 15(8):1073-1084. PubMed ID: 28088913
[TBL] [Abstract][Full Text] [Related]
53. Long-term safety and tolerability of aripiprazole lauroxil in patients with schizophrenia.
Nasrallah HA; Aquila R; Du Y; Stanford AD; Claxton A; Weiden PJ
CNS Spectr; 2019 Aug; 24(4):395-403. PubMed ID: 30109845
[TBL] [Abstract][Full Text] [Related]
54. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
Tandon R; Marcus RN; Stock EG; Riera LC; Kostic D; Pans M; McQuade RD; Nyilas M; Iwamoto T; Crandall DT
Schizophr Res; 2006 May; 84(1):77-89. PubMed ID: 16483745
[TBL] [Abstract][Full Text] [Related]
55. [Efficacy of aripiprazole for the treatment of schizophrenia: what dose is required?].
Charpeaud T; Samalin L; Llorca PM
Encephale; 2014 Feb; 40(1):62-73. PubMed ID: 24445245
[TBL] [Abstract][Full Text] [Related]
56. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA).
Wolf J; Janssen F; Lublin H; Salokangas RK; Allain H; Smeraldi E; Bernardo M; Millar H; Pans M; Adelbrecht C; Laughton J; Werner C; Maier W
Curr Med Res Opin; 2007 Oct; 23(10):2313-23. PubMed ID: 17706003
[TBL] [Abstract][Full Text] [Related]
57. Rationale and design of the PLACID study: a randomised trial comparing the efficacy and safety of inhaled loxapine versus IM aripiprazole in acutely agitated patients with schizophrenia or bipolar disorder.
San L; Estrada G; Oudovenko N; Vieta E
BMC Psychiatry; 2017 Apr; 17(1):126. PubMed ID: 28376877
[TBL] [Abstract][Full Text] [Related]
58. Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies.
Costamagna I; Calisti F; Cattaneo A; Hsu J; Tocco M; Pikalov A; Goldman R
Eur Psychiatry; 2021 May; 64(1):e35. PubMed ID: 33966678
[TBL] [Abstract][Full Text] [Related]
59. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study.
Vieta E; Owen R; Baudelet C; McQuade RD; Sanchez R; Marcus RN
Curr Med Res Opin; 2010 Jun; 26(6):1485-96. PubMed ID: 20429835
[TBL] [Abstract][Full Text] [Related]
60. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study.
Keck PE; Orsulak PJ; Cutler AJ; Sanchez R; Torbeyns A; Marcus RN; McQuade RD; Carson WH;
J Affect Disord; 2009 Jan; 112(1-3):36-49. PubMed ID: 18835043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
